Targeting Undruggable Cancer Targets with RNA Therapeutics
At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed. Our company was built upon our deep experience and know-how in this space and we are well-positioned to advance candidates against targets considered “undruggable” by conventional chemistries.
Flamingo has the most advanced antisense RNA-targeting oncology portfolio with three clinical programs targeting undruggable transcription factors and splice variants. We also have a proprietary discovery engine, FLAME™ (Flamingo LncRNA Antisense Mining Engine), that addresses lncRNAs, a large and untapped class of disease-causing targets within the “dark matter” of the human genome. The Company was founded in 2020 based on pioneering work in the field of lncRNAs in oncology with our academic partners at VIB, KU Leuven, Ghent University and The University of Michigan. Flamingo has a strategic partnership with Ionis Pharmaceuticals and is supported by well-known biotechnology investors Kurma Partners and PMV. The company is headquartered in Belgium with additional operations in San Diego, CA